Exact Sciences Corporation (EXAS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 64.00 |
| Open | 63.80 |
| Bid | 66.91 x 900 |
| Ask | 67.00 x 900 |
| Day's Range | 62.76 - 67.03 |
| 52 Week Range | 43.90 - 100.77 |
| Volume | |
| Avg. Volume | 1,451,784 |
| Market Cap | 12.122B |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings Date | Feb 19, 2024 - Feb 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 92.69 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
Related Research
- Exact Sciences CorporationAnalyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.RatingFair ValueEconomic Moat14 days agoMorningstar
ZacksWhy Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insider MonkeyExact Sciences Corporation (EXAS) Shares Pulled Back in Q3
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned -7.98%, Advisor Class fund APDSX posted a return of -7.96%, and Institutional Class fund APHSX returned -7.97%, compared to a […]
PR NewswireExact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium (SABCS).
